Gara Jalqabaatti › Myeloma Baay’ee › Tennessee › Nashville
Qorannoo klinikaalii Myeloma Baay’ee Nashville, TN keessatti
Qorannoo 32 Myeloma Baay’ee f Nashville fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Nashville
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Namoota walitti qabaa jiraSadarkaa 4
- Sarah Cannon Research Institute, Nashville
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Tennessee Oncology, PLLC, Nashville
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Nashville
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 3
- Henry-Joyce Cancer Clinic, Nashville
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Namoota walitti qabaa jiraSadarkaa 2/3
- SCRI Oncology Partners /ID# 278353, Nashville
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Nashville
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Namoota walitti qabaa jiraSadarkaa 2
- GSK Investigational Site, Nashville
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Namoota walitti qabaa jiraSadarkaa 3
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- fi 2 dabalataa
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Namoota walitti qabaa jiraSadarkaa 2
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Namoota walitti qabaa jiraSadarkaa 1/2
- GSK Investigational Site, Nashville
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Nashville
- Research Site, Nashville
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Nashville
- Research Site, Nashville
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 3
- Vanderbilt-Ingram Cancer Center (VICC), Nashville
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 2
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- TriStar Centennial Medical Center, Nashville
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Vanderbilt-Ingram Cancer Center, Nashville
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
Qorannoo Myeloma Baay’ee magaalota biroo keessatti
- New York City, NYQorannoo 60
- Boston, MAQorannoo 42
- Atlanta, GAQorannoo 42
- Houston, TXQorannoo 38
- Durham, NCQorannoo 37
- Denver, COQorannoo 27
- Rochester, MNQorannoo 24
- St. Louis, MOQorannoo 24
- Columbus, OHQorannoo 24
- Baldwin Park, CAQorannoo 23
- Edison, NJQorannoo 22
- Chicago, ILQorannoo 22
Qorannoo biroo Nashville keessatti
- Kansara Qara'a Non-Small CellQorannoo 97
- Saree OljooQorannoo 81
- Kansara MetastatikiiQorannoo 70
- Kansarii ColorectalQorannoo 69
- Saree (Gosoota Hunda)Qorannoo 65
- Kansarii OvariiQorannoo 49
- Kansarii ProstateQorannoo 43
- Dhibee QaraQorannoo 40
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 39
- Kansarii PancreasQorannoo 39
- Kansa EndometiriyaaliiQorannoo 38
- MelanomaQorannoo 33
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.